- InterView
- "Gilead-Kite will lead the trt landscape for DLBCL in KOR"
- by Hwang, byoung woo Sep 10, 2025 06:12am
- With the approval of the CAR-T cell therapy Yescarta (axicabtagene ciloleucel) in Korea, a shift in the treatment landscape for Diffuse Large B-cell Lymphoma (DLBCL) is anticipated. Analysis suggests that an innovative therapeutic option that has demonstrated higher cure rates and improved survival compared to existing second-line treatments
- Company
- Launch of K-new drugs in the Chinese market is accelerated
- by Chon, Seung-Hyun Sep 10, 2025 06:12am
- New drugs developed in Korea are successively entering the Chinese market. Based on their commercial success in the Korean market, new P-CAB (Potassium-Competitive Acid Blocker) drugs for gastroesophageal reflux disease are quickly entering the approximately KRW 3 trillion-worth Chinese market. Fexuclue has become the second P-CAB to enter the C
- Company
- KIPO, IPTAB to introduce ‘advance invalidation notice’
- by Hwang, byoung woo Sep 9, 2025 06:13am
- The Korean Intellectual Property Office (KIPO) and the Intellectual Property Trial and Appeal Board (IPTAB) announced a reform plan introducing a pre-announcement system for invalidation decisions (“advance invalidation notice”) in patent invalidation trials, dividing opinions within the pharmaceutical industry. Led by the Korea Pharmace
- Opinion
- [Reporter's View] Interest Rate Cuts and Investment Revival
- by Kim, Jin-Gu Sep 9, 2025 06:13am
- Will the long wait finally come to an end? With growing expectations that the U.S. Federal Reserve will lower its benchmark interest rate, optimism is rising that frozen investor sentiment could finally thaw. The Korean pharmaceutical and biotech sector, particularly bio-ventures with strained finances, has endured severe challenges. As e
- Company
- Interest in Wegovy and Mounjaro rises at KSSO conference
- by Kim, Jin-Gu Sep 9, 2025 06:12am
- On the morning of September 5 at Conrad Hotel, Yeongdeungpo, Seoul, a long line formed in front of the registration desk for the Autumn Conference of the Korean Society for the Study of Obesity (KSSO). With more than 1,000 pre-registered attendees, the conference drew continuous interest from healthcare professionals from the very first day
- Company
- "Effect of Bavencio on long-term survival confirmed"
- by Son, Hyung Min Sep 9, 2025 06:12am
- At the conference held in Korea, Bavencio's real-world data (RWD) have been unveiled, extending beyond its initial trial that served as the basis for approval. Bavencio maintenance therapy has been shown to prolong the lives of patients with urothelial carcinoma in multiple countries, including Korea, Japan, France, and the U.S. Notably, the
- Company
- Bispecific Ab 'Epkinly' for DLBCL available at gen hospitals
- by Eo, Yun-Ho Sep 8, 2025 06:17am
- 'Epkinly,' a new innovative drug that is a T-cell-engaging bispecific antibody, is now available for prescription at general hospitals. According to industry sources, AbbVie Korea's Epkinly (epcoritamab), the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), passed the drug committees (DC) of tertiary general hosp
- Company
- Competitiveness of K-anticancer drugs reaffirmed
- by Son, Hyung Min Sep 8, 2025 06:17am
- Korean pharmaceutical companies gathered in one place to show off their anti-cancer pipelines, including both in-house developed and imported new drugs. At the Korean Society of Medical Oncology 2025 International Conference (KSMO 2025), which was held over three days from September 3 at Walkerhill Hotel in Seoul, major domestic pharmaceu
- Company
- Kerendia+Jardiance combo demonstrates early benefit
- by Hwang, byoung woo Sep 8, 2025 06:16am
- Kerendia (finerenone), a treatment for chronic kidney disease, has strengthened its clinical presence by demonstrating efficacy in combination with the SGLT-2 inhibitor Jardiance (empagliflozin). Kerendia is the first non-steroidal mineralocorticoid receptor antagonist (MRA), with a novel mechanism of action that directly suppresses infla
- Policy
- Six strengths of obesity drug Mounjaro Quick Pen approved
- by Lee, Hye-Kyung Sep 8, 2025 06:16am
- Following its launch in Korea, Eli Lilly has expanded the product lineup of its obesity treatment Mounjaro (tirzepatide) by receiving approval for the Mounjaro QuickPen formulation. On September 5, the Ministry of Food and Drug Safety approved 6 QuickPen doses: 2.5 mg/0.6 ml, 5 mg/0.6 ml, 7.5 mg/0.6 ml, 10 mg/0.6 ml, 12.5 mg/0.6 ml, and 1
